AAO Updates HCQ Retinopathy Guidance
Updated recommendations emphasize dosing limits and screening for toxicity risk.
-
By
-
Andrea Surnit
-
April 23, 2026
-
Objective:
To update screening recommendations for hydroxychloroquine (HCQ) retinopathy based on recent advances in retinal imaging and artificial intelligence.
Approach:
Key Findings:
- Risk of HCQ retinopathy is less than 1% within 5 years and less than 2% within 10 years at doses up to 5 mg/kg/day.
- Annual risk remains below 5% after 20 years for patients without prior toxicity.
- Risk of toxicity increases with higher doses, longer durations, renal disease, and older age at treatment initiation.
Interpretation:
With proper dosing and annual screening, most patients can safely use HCQ for extended periods with a low risk of retinal toxicity.
Limitations:
- Risk estimates depend on adherence to dosing and screening.
- Newer AI-based imaging technologies are not yet fully validated for routine clinical use.
Conclusion:
Baseline screening is recommended at treatment initiation, with annual follow-ups, although screening may be deferred for low-risk patients.
Sources:
